CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
Aceclidine+tropicamide combination +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03201562
NCT03201562Phase 2Completed
CompareCT.gov

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

LENZ Therapeutics, Inc·interventional·Posted Jun 28, 2017·Updated Sep 22, 2022

In Brief

A Phase 2 clinical trial evaluating Aceclidine+tropicamide combination, Aceclidine, and 1 other intervention for Presbyopia. Completed, enrolled 58 participants across 1 site.

Detailed Summary

To evaluate the safety and efficacy of PRX-100 compared with aceclidine alone and vehicle in the treatment of early to moderate presbyopia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 28, 2017
Enrollment StartApr 30, 2017
Primary CompletionMay 20, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.0 years ago

Interventions

Aceclidine+tropicamide combinationdrug

Ophthalmic Solution

Aceclidinedrug

Ophthalmic Solution

Vehicledrug

Ophthalmic Solution